LON:BPCP

BioPharma Credit (BPCP) Share Forecast, Price & News

Today's Range: N/A
50-Day Range: 72.63
▼
80.57
52-Week Range: N/A

Volume: 86,487 shs
Average Volume: 30,053 shs
Market Capitalization: £994.98 million

P/E Ratio: 1,210.43
Dividend Yield: 7.34%
Price Target: N/A

About BioPharma Credit (LON:BPCP) Stock

BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in Exeter, the United Kingdom.

Receive BPCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioPharma Credit and its competitors with MarketBeat's FREE daily newsletter.

BPCP Stock News Headlines

May 28, 2023 | americanbankingnews.com

BioPharma Credit (LON:BPCP) Stock Price Down 3%

May 7, 2023 | americanbankingnews.com

BioPharma Credit (LON:BPCP) Hits New 52-Week Low at $71.68

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

April 20, 2023 | americanbankingnews.com

BioPharma Credit (LON:BPCP) Reaches New 1-Year Low at $75.99

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: N/A
Sub-Industry: N/A
Sector: N/A
Current Symbol: LON:BPCP
CUSIP: N/A
CIK: N/A
Web: www.bpcruk.com
Phone: 44 13 9247 7500
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX 0.06
Trailing P/E Ratio: 1,210.43
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £182.31 million
Net Margins: 83.56%
Pretax Margin: N/A
Return on Equity: 13.50%
Return on Assets: 8.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.34
Quick Ratio: 14.07

Sales & Book Value

Annual Sales: £218.17 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 98.00
Book Value: GBX 101 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,370,000,000
Free Float: N/A
Market Cap: £994.98 million
Optionable: Not Optionable
Beta: 0.23

Key Executives

Mr. Pedro Gonzalez de Cosio
Investment Mang.

Mr. Pablo Gerardo Legorreta (Age 58)
Investment Mang.

Mr. Martin G. Friedman (Age 57)
Investment Mang.

BPCP Stock - Frequently Asked Questions

Is BioPharma Credit a good dividend stock?: BioPharma Credit (LON:BPCP) pays an annual dividend of GBX 0.07 per share and currently has a dividend yield of 7.34%. BPCP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 116.67%. Payout ratios above 75% are not desirable because they may not be sustainable.
What is BioPharma Credit's stock symbol?: BioPharma Credit trades on the London Stock Exchange (LON) under the ticker symbol "BPCP."

How do I buy shares of BioPharma Credit?: Shares of BPCP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
How much money does BioPharma Credit make?: BioPharma Credit (LON:BPCP) has a market capitalization of £0.00 and generates £218.17 million in revenue each year. The company earns £182.31 million in net income (profit) each year or GBX 0.06 on an earnings per share basis.
How can I contact BioPharma Credit?: The official website for the company is www.bpcruk.com. The company can be reached via phone at 44 13 9247 7500.

This page (LON:BPCP) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial